Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.

Abstract

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

• Authors: Sijia Li, Xueqin Chen, Penghua Hu, Suijing Wu, Jianchao Ma, Zhuo Li, Xiuchuan Wu, Feng Wen, Xia Fu, Zhonglin Feng, Yiming Tao, Bohou Li, Lei Fu, Renwei Huang, Chaosheng He, Wei Shi, Xinling Liang, Shuangxin Liu
• Journal: Blood purification (Blood Purif) Vol. 51 Issue 2 Pg. 189-192 ( 2022) ISSN: 1421-9735 [Electronic] Switzerland
• PMID: 34500449 (Publication Type: Case Reports, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 S. Karger AG, Basel.

Chemical References

• Isoquinolines
• Recombinant Proteins
• Erythropoietin
• Glycine
• roxadustat

Topics

• Aged
• Erythropoietin (therapeutic use)
• Glycine (analogs & derivatives)
• Humans
• Isoquinolines
• Male
• Recombinant Proteins
• Red-Cell Aplasia, Pure (drug therapy, etiology)
• Renal Dialysis (adverse effects)